期刊文献+

单次负荷量他汀对稳定型心绞痛患者PCI术后炎症反应、血小板活性及心脏事件的影响 被引量:5

Effect of preoperative single intensive statin on postoperative serum inflammation factors,platelet activity and major adverse cardiac events in stable angina patients after percutaneous coronary intervention
下载PDF
导出
摘要 目的观察已接受长期他汀治疗的稳定型心绞痛患者,经皮冠状动脉介入术(percutaneous coronary interven-tion,PCI)前单次服用80 mg阿托伐他汀能否降低术后炎症反应、血小板活性以及主要不良心脏事件(major adverse cardiacevents,MACE)的发生。方法选择2010年1月至2011年7月在本科接受PCI术的稳定型心绞痛患者115例,年龄(59.23±10.23)岁,男性83例,女性32例。随机分为2组:强化组(n=56)在PCI术前12 h给予单次负荷剂量(80 mg)阿托伐他汀;对照组(n=59)在PCI术前12 h予常规剂量(20 mg)阿托伐他汀治疗。观察2组患者术前24 h及术后24 h血白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、高敏C反应蛋白(hs-CRP)及血小板α颗粒膜蛋白(GMP140)、p-选择素(CD62p)水平,并随访所有患者术后30 d内MACE的发生情况。结果 2组术前24 h各指标无差异(P>0.05)。强化组术后24 h炎症因子及血小板活化因子显著低于对照组(P<0.05);强化组炎症因子及血小板活化因子水平在PCI术后较术前显著下降(P<0.05)。对照组术后较术前有一定程度的升高(P>0.05);术后30 d强化组MACE发生率显著低于对照组(P<0.05)。结论对于已接受长期他汀治疗的稳定型心绞痛患者,PCI术前12 h再给予单次80 mg阿托伐他汀能显著降低炎症因子、血小板活化因子及MACE的发生。 Objective To investigate whether a single loading of 80 mg atorvastatin before receiving percutaneous coronary intervention (PCI) can reduce postoperative inflammation, platelet activity and incidence of major adverse cardiac events (MACE) in stable angina patients who had accepted a long-term statin therapy. Methods One hundred and fifteen patients with chronic stable angina who underwent PCI in our department from Jan. 2010 to Jul. 2011 were prospectively selected. The patients were divided into the intensive statin group ( a single loading of 80 mg atorvastatin in 12 h before receiving PCI) and the standard group ( a routinedosage of 20 mg atorvastatin at same time point). Serum levels of interleukin-6 (IL-6), high sensitivity C-reac- tive protein( hs-CRP), tumor necrosis factor-or (TNF-cO, GMP140 and p-selectin (CD62p) were measured in 24 h before and 24 h after PCI in all patients. The incidence of MACE was observed in 30d after surgery. Results The basic clinical data and PCI basic characteristics between the two groups showed no obvious difference ( P 〉 0. 05 ). When compared with those in the standard group, the levels of inflammation and platelet activation factors were lower in the intensive statin group after 24 h (P 〈 0. 05 ). The levels of inflammation and platelet activation factors at 24 h after PCI were lower than before PCI in the intensive statin group ( P 〈 0. 05). While the levels of inflammation and platelet activation factors at 24 h after PCI showed a rising trend than before PCI in the standard group( P 〉 0. 05 ). The incidence of MACE in the intensive group was lower than that in the standard group(P 〈 0. 05). Conclusion Before receiving PCI, a single loading of 80 mg atorvastatin reduces inflammation , platelet activity and incidence of MACE in patients with stable angina who had accepted the long-term statins therapy.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2012年第2期161-164,共4页 Journal of Third Military Medical University
基金 重庆市卫生局重点项目(2009-1-13) 2010重庆医科大学校级重点项目(XBZD.201010)~~
关键词 阿托伐他汀 经皮冠状动脉介入术 炎性因子 血小板活化 主要不良心脏事件 atorvastatin percutaneous coronary intervention inflammation factor platelet activation factor major adverse cardiac events
  • 相关文献

参考文献21

  • 1Pasceri V,Patti G,Nusca A,et al.Randomized trial of atorvastatin forreduction of myocardial damage during coronary intervention:resultsfrom the ARMYDA(Atorvastatin for Reduction of Myocardial Damageduring Angioplasty)study[J].Circulation,2004,110(6):674-678.
  • 2Forrester J S.Libby P.The inflammation hypothesis and its potentialrelevance to statin therapy[J].Am J Cardiol,2007,99(5):732-738.
  • 3Patti G,Pasceri V,Colonna G,et al.Atorvastatin pretreatment im-proves outcomes in patients with acute coronary syndromes undergoingearly percutaneous coronary intervention:results of the ARMYDA-ACSrandomized trial[J].J Am Coll Cardiol,2007,49(12):1272-1278.
  • 4Di-Sciascio G,Patti G,Pasceri V,et al.Efficacy of atorvastatin reloadin patients on chronic statin therapy undergoing percutaneous coronaryintervention:results of the ARMYDA-RECAPTURE(Atorvastatin forReduction of Myocardial Damage During Angioplasty)Randomized Tri-al[J].J Am Coll Cardiol,2009,54(6):558-565.
  • 5Patti G,Chello M,Pasceri V,et al.Protection from procedural myo-cardial injury by atorvastatin is associated with lower levels of adhesionmolecules after percutaneous coronary intervention:results from theARMYDA-CAMs(Atorvastatin for Reduction of Myocardial Damageduring Angioplasty-Cell Adhesion Molecules)substudy[J].J Am CollCardiol,2006,48(8):1560-1566.
  • 6Heeba G,Hassan M K,Khalifa M,et al.Adverse balance of nitric ox-ide/peroxynitrite in the dysfunctional endothelium can be reversed bystatins[J].J Cardiovasc Pharmacol,2007,50(4):391-398.
  • 7Westerweel P E,Visseren F L,Hajer G R,et al.Endothelial progeni-tor cell levels in obese men with the metabolic syndrome and the effectof simvastatin monotherapy vs.simvastatin/ezetimibe combination ther-apy[J].Eur Heart J,2008,29(22):2808-2817.
  • 8Kagami S,Kanari H,Suto A,et al.HMG-CoA reductase inhibitor sim-vastatin inhibits proinflammatory cytokine production from murine mastcells[J].Int Arch Allergy Immunol,2008,146(Suppl 1):61-66.
  • 9Rodriguez-Vita J,Sanchez-Galan E,Santamaria B,et al.Essentialrole of TGF-beta/Smad pathway on statin dependent vascular smoothmuscle cell regulation[J].PLoS One,2008,3(12):e3959.
  • 10Brigueri C,Visconti G,Focaccio A,et al.Novel approaches for pre-venting or limiting events(Naples)Ⅱtrial:impact of a single highloading dose of atorvastatin on periprocedural myocardial infarction[J].J Am Coll Cardiol,2009,54(23):2157-2163.

二级参考文献44

共引文献45

同被引文献44

  • 1马建新,郭丹杰,郑兴征,郭继鸿.急性心肌梗死患者冠脉急诊介入术后ST段回落的研究[J].临床心电学杂志,2006,15(1):22-26. 被引量:10
  • 2王禹,盖鲁粤,沈洪,计达,黄先勇,苏绍萍,武建军,张志强,陈威,刘长福,殷宗健,李天德.国产氯吡格雷在急性心肌梗死急诊冠脉介入治疗过程中的有效性及对血小板聚集功能的影响[J].中国急救医学,2006,26(7):512-514. 被引量:15
  • 3柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2143
  • 4李立志.氯吡格雷在预防冠心病介入治疗心血管不良事件发生中的疗效观察[J].中国药物经济学,2012(2):189-190.
  • 5齐丽平.高负荷氯吡格雷联合替罗非班在非趼段抬高型急性冠脉综合征经皮冠状动脉介入治疗中的作用[J].中国实用诊断与治疗杂志j2012,26(12):1180-1182.
  • 6Simone P,MartijnСP,Ben J,et al.Early statin treatment prior to primary PCI for acute myocardial infarction:REPERATOR,a randomized placebo-controlled pilot trial[J].Catheter Cardiovasc Interv,2012,80(5):756-765.
  • 7Nafasi L,Rahmani R,Shafiee A,et al.Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction[J].Curr Med Res Opin,2014,30(3):381-386.
  • 8Ye H,He F,Fei X,et al.High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period[J].J Cardiovasc Pharmacol Ther,2014,19(3):290-295.
  • 9Sardella G,Lucisano L,Mancone M,et al.Comparison of high reloading RO suvastatin and atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of Myoc Ardial periprocedural necrosis.the ROMA II trial[J].Int J Cardiol,2013,168(4):3715-3720.
  • 10Cay S,Durmaz T,Canpolat U,et al.High dose statins should be used in all patients undergoing percutaneous coronary intervention[J].Int J Cardiol,2013,168(5):5103-5104.

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部